Navigation Links
Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects
Date:12/16/2009

EVANSTON, Ill., Dec. 16 /PRNewswire/ -- Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor(1). The studies also showed that GLYX-13's antidepressant effects were evident within 20 minutes of administering a single dose and that it affected both the positive and negative symptoms of depression, while also demonstrating a lasting antidepressant effect. GLYX-13 is a glycine site functional partial agonist (GFPA) modulator of the NMDA receptor, a novel and selective mechanism discovered by Naurex scientists. GLYX-13 is initially being developed as a therapy for treatment-resistant depression. Separately, Naurex today announced that it has initiated a Phase I clinical trial to evaluate the safety of GLYX-13 in healthy volunteers.

"The NMDA receptor has long been a target for new treatments for CNS disorders, but the strong efficacy achieved by modulating the NMDA receptor has been accompanied by serious side effects such as schizophrenia-like symptoms, which has limited their use," said Ronald Burch, MD, PhD, chief medical officer at Naurex. "To overcome this problem, our founder Dr. Joseph Moskal used a unique approach to identify GLYX-13, a novel and selective modulator of the NMDA receptor. These new data demonstrate robust antidepressant activity by GLYX-13 with no signs of CNS side effects at any dose tested--an extraordinary early result. From a clinical perspective, we are also excited by the ability of GLYX-13 to alleviate both positive and negative symptoms of depression in these animal models, as well as by its very rapid onset o
'/>"/>

SOURCE Naurex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Developed by Roche under the trade name ... in the world. In Feb.26, 2010, it was approved ... injections available in China all ...
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final recognition ... Contact Lens Health Week, 1-800 Contacts is sharing how ... that contact lens wearers who do not properly care ... for eye infections. Most contact lens ... but a clean lens case is sometimes overlooked.  When ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... S.C., April 12, 2011 Southern Home Medical ... healthcare services, healthcare professionals and equipment to medical ... results from operations for fiscal year 2010 have ... from Encore Medical Staffing. In a ...
... ST. PAUL, Minn., April 12, 2011 According to ... safety edit, designed to require provider prior authorization (PA) ... use of insulin or nitrate (CIN), potentially decreased members, ... at the Academy of Managed Care Pharmacy,s 23rd Annual ...
Cached Medicine Technology:Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010 2Point-of-Sale Electronic Safety Check May Reduce Heart Attack Risk for Diabetic Patients 2
(Date:8/30/2015)... , ... August 30, 2015 , ... ... (HIFU) medical devices for the treatment of prostate cancer, has announced the roll-out ... summer at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... Irvine, CA (PRWEB) , ... August 29, 2015 , ... ... on a mission. His mission is to increase acceptance of the chiropractic field ... pain medications that further debilitate them. Although Chiropractic was made available to the ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... obstructive pulmonary disease (including emphysema), or asthma, are at higher risk from wildfire ... heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College joined nine ... experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models ... the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... , , TAMPA, Fla., July 23 ... scrubs and chemical drugs and armed himself with a movie ... due to preventable illness, Burton found an alarming connection between ... of death. Now he,s going to tell the world what ...
... recent years. This is fact, but what is not clear ... have shown that family conflict is not a significant factor. ... striking: in Spain, 24% of women take antidepressants and more ... is often related to family or work-related problems. We wanted ...
... Ind., July 23 Hill-Rom Holdings, Inc.,s, (NYSE: HRC ) ... 2009. You are invited to participate in a webcast the following ... Earnings Release: Hill-Rom Holdings, Inc.,s Fiscal 2009 Third Quarter ... the public after the NYSE close on Thursday, August 6, 2009. ...
... YORK, July 23 The U.S. Fund for UNICEF announced today ... UNICEF,s mission to save, protect and improve the lives of children ... reducing the number of preventable deaths of children, from 25,000 per ... will lead the steering committee and host UNICEF,s Next Generation launch ...
... July 23 At the 2009 American Association of ... Anaheim, California, Elekta will demonstrate how the company,s comprehensive ... cancer care with precision and ease. , , ... deliver radiation treatments, Elekta booth 423 will highlight treatment ...
... , WARREN, N.J., July 23 MonoSol Rx, the ... dissolving thin film pharmaceutical products, today announced the appointment of Theodore ... will report to Keith J. Kendall, Executive Vice President and CFO. ... are pleased to welcome Ted to MonoSol Rx and look forward ...
Cached Medicine News:Health News:Nurse Turned Filmmaker Makes Lifesaving Film 2Health News:Almost 1 quarter of Spanish women take antidepressants 2Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Third Quarter Earnings Webcast 2Health News:U.S. Fund for UNICEF and Jenna Bush Hager Announce Next Generation Initiative to Improve Lives of Children Around the World 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 2Health News:Comprehensive VMAT Solution From Elekta on Center Stage at 2009 AAPM Annual Meeting 3Health News:MonoSol Rx Appoints Theodore Clemente Vice President Business Development 2Health News:MonoSol Rx Appoints Theodore Clemente Vice President Business Development 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: